Compare Adaptive Biotechnologies Corp (ADPT) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Valero Energy Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Valero Energy Corporation trades at $278.48 (market cap $79.05B). The key difference: Valero Energy Corporation is far larger — about 23.7× Adaptive Biotechnologies Corp's market cap, and Valero Energy Corporation pays a 1.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VLO | |
|---|---|---|
Market Cap | $3.33B | $79.05B |
Sector | Health | Energy |
52-Week High | $22.37 | $270.32 |
52-Week Low | $10.24 | $131.77 |
Enterprise Value | $3.19B | $84.81B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Valero Energy (VLO) trades at $266.22, down 0.58% on the day, with strong technical momentum showing bullish moving averages and key resistance at $270. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.08 EPS. Fundamentals show solid profitability with 17.72% ROE and attractive valuation metrics including P/E of 19.75 and P/S of 0.66. Recent news highlights VLO's refining strength and renewable fuels growth potential.
VLO presents a compelling investment case with strong analyst support (58% buy ratings) and a consensus price target of $258.25. The company's Gulf Coast refining advantage and clean-fuel initiatives support long-term growth, though investors face risks from energy market volatility and declining revenue trends from $176.4B in 2022 to $122.7B in 2025. The current price near resistance levels suggests potential for breakout or consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
